Last reviewed · How we verify
NCT04984148
Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC
trial testing CT in Stage III Non-small Cell Lung Cancer in 70 participants. Status unknown.
30 September 2022
Quick facts
| Lead sponsor | Guangdong Provincial People's Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 1 February 2019 |
| Primary completion | 30 September 2022 |
| Estimated completion | 31 January 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- CT
Conditions studied
- Stage III Non-small Cell Lung Cancer — all drugs for Stage III Non-small Cell Lung Cancer →
Sponsor
Guangdong Provincial People's Hospital
Who can join
18 and older, any sex, with Stage III Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Consolidation immunotherapy of immune checkpoint inhibitor (ICI) following chemoradiotherapy (CRT) is the current standard of care for patients with unresectable locally advanced non-small cell lung cancer (NSCLC) as it improves both progression-free survival and overall survival. However, a substantial proportion of patients still experience disease recurrence despite consolidation ICI. It is important for personalized treatment to predict the efficacy of consolidation ICI. PD-L1 expression is used as a predictive biomarker for ICI response and efficacy in advanced NSCLC, but its role in patients with stage III disease is unclear. One important reason is PD-L1 testing performed on pre-CRT tissue may not reflect changes in PD-L1 expression after CRT. CT-based radiomics approaches have been successfully applied to generate imaging biomarkers as decision support tools for clinical practice. The hypothesis of this study is that CT radiomics model can assess PD-L1 status after CRT and predict the efficacy of CRT combined with ICI in unresectable locally advanced NSCLC.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria.
Castello A, Castellani M, Florimonte L, Urso L, et al · · 2022 · cited 20× · PMID 35330068 · DOI 10.3390/jcm11061740 -
Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians.
Zhou H, Luo Q, Wu W, Li N, et al · · 2023 · cited 6× · PMID 36936913 · DOI 10.3389/fimmu.2023.1088874
Verify or expand the search:
- PubMed search for NCT04984148
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CT
Trials testing the same drug.
- NCT06308094 — 320-detector Computed Tomography to Assess Myocardial Extracellular Volume Fraction in Patients With Atrial Fibrillation · NA · recruiting
- NCT06696677 — Small Intestine Length Measurement Using 3D CT Volumetry and in Vivo Measurement Using Pre-marked Graspers in Revisional · NA · recruiting
- NCT06537193 — Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment · NA · recruiting
- NCT06597877 — CT Temporal Bone Anatomical Variations · not yet recruiting
- NCT06081855 — Predictors of Aortic Root Dilatation in Tetralogy of Fallot Patients · unknown
Other recruiting trials for Stage III Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06917573 — PALACE: Cemiplimab Trial According to ctDNA Levels · Phase 2 · recruiting
- NCT05468242 — Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizum · Phase 2 · recruiting
Other Guangdong Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
- NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
- NCT07352930 — A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Can · NA · not yet recruiting
- NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
- NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04984148 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial People's Hospital
- Last refreshed: 9 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04984148.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing